1. Home
  2. DXYZ vs NPCE Comparison

DXYZ vs NPCE Comparison

Compare DXYZ & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DXYZ
  • NPCE
  • Stock Information
  • Founded
  • DXYZ N/A
  • NPCE 1997
  • Country
  • DXYZ
  • NPCE United States
  • Employees
  • DXYZ N/A
  • NPCE N/A
  • Industry
  • DXYZ
  • NPCE Medical Specialities
  • Sector
  • DXYZ
  • NPCE Health Care
  • Exchange
  • DXYZ Nasdaq
  • NPCE Nasdaq
  • Market Cap
  • DXYZ 363.6M
  • NPCE 328.8M
  • IPO Year
  • DXYZ 2024
  • NPCE 2021
  • Fundamental
  • Price
  • DXYZ $23.74
  • NPCE $13.51
  • Analyst Decision
  • DXYZ
  • NPCE Strong Buy
  • Analyst Count
  • DXYZ 0
  • NPCE 7
  • Target Price
  • DXYZ N/A
  • NPCE $17.00
  • AVG Volume (30 Days)
  • DXYZ N/A
  • NPCE 221.9K
  • Earning Date
  • DXYZ N/A
  • NPCE 11-04-2025
  • Dividend Yield
  • DXYZ N/A
  • NPCE N/A
  • EPS Growth
  • DXYZ N/A
  • NPCE N/A
  • EPS
  • DXYZ N/A
  • NPCE N/A
  • Revenue
  • DXYZ N/A
  • NPCE $94,864,000.00
  • Revenue This Year
  • DXYZ N/A
  • NPCE $22.13
  • Revenue Next Year
  • DXYZ N/A
  • NPCE $6.07
  • P/E Ratio
  • DXYZ N/A
  • NPCE N/A
  • Revenue Growth
  • DXYZ N/A
  • NPCE 24.08
  • 52 Week Low
  • DXYZ N/A
  • NPCE $6.63
  • 52 Week High
  • DXYZ N/A
  • NPCE $18.98
  • Technical
  • Relative Strength Index (RSI)
  • DXYZ 42.12
  • NPCE 72.36
  • Support Level
  • DXYZ $23.40
  • NPCE $12.52
  • Resistance Level
  • DXYZ $25.54
  • NPCE $13.78
  • Average True Range (ATR)
  • DXYZ 1.45
  • NPCE 0.66
  • MACD
  • DXYZ -0.12
  • NPCE 0.34
  • Stochastic Oscillator
  • DXYZ 8.88
  • NPCE 93.02

About DXYZ Destiny Tech100 Inc. Common Stock

Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.

About NPCE Neuropace Inc.

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Share on Social Networks: